ORMP - Oramed: NASH Biotech Play With Added Bonus
Summary
- Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary exploratory biomarker endpoints established proof of concept.
- Results from the phase 3 study using ORMD-0801 for the treatment of patients with Type 2 Diabetes are expected in January of 2023.
- ORMD-0901 is an oral GLP-1 drug for the treatment of patients with Type 2 Diabetes.
- Oramed had $160 million in cash as of September 30, 2022. It believes it has enough cash to fund its operations for at least the next 12 months.
For further details see:
Oramed: NASH Biotech Play With Added Bonus